FDA Approves Lynparza to Treat BRCA-mutated Metastatic Breast Cancer

FDA Approves Lynparza to Treat BRCA-mutated Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib) for a difficult-to-treat form of metastatic breast cancer. Patients with BRCA-mutated, HER2-negative breast cancer who have previously been treated with chemotherapy are now approved to be treated with Lynparza. The FDA’s approval is based on data showing that Lynparza — developed by AstraZeneca working

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *